GenSight Biologics appoints Mohamed Genead as chief medical officer

4 May 2017

Paris, France-based GenSight Biologics (Euronext: SIGHT) has appointed Mohamed Genead, the former head of ophthalmology/retina gene therapy at Biogen (Nasdaq: BIIB) as the company’s new chief medical officer.

GenSight is a biopharmaceutical company focused on developing gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system.

Dr Genead, who will be report directly to the chief executive as part of the executive committee, will oversee clinical development and medical affairs at the company.

At Biogen, he acted as the strategic R&D partner for the business unit and was responsible for the growth of the therapeutic portfolio. Prior to this Dr Genead spent eight years at Allergan (NYSE: AGN) as the executive medical director in charge of global clinical development for the ophthalmology/retina therapeutic area.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK